A phase II study with 5-fluorouracil, folinic acid and oxaliplatin (FOLFOX-4 regimen) in patients with metastatic renal cell carcinoma

Oncology

Volumn 64, Issue 1, 2003, Pages 25-27

  Bennouna, Jaafar ^a   Delva, R ^b   Gomez, F ^c   Lesimple, T ^d   Geoffrois, L ^e   Linassier, C ^f   Chevreau, C ^g   Douillard, J Y ^c   Negrier S ^c  

^a CENTRE RENÉ GAUDUCHEAU   (France)

^b CENTRE PAUL PAPIN   (France)

^c CENTRE LÉON BÉRARD   (France)

^d CENTRE EUGÈNE MARQUIS   (France)

^e CENTRE ALEXIS VAUTRIN   (France)

^f CHU BRETONNEAU   (France)

^g INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

5 FU; Metastatic renal cell carcinoma; Oxaliplatin

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; EPISTAXIS; FEMALE; FEVER; HEART MUSCLE ISCHEMIA; HUMAN; KIDNEY CARCINOMA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY DYSFUNCTION; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; FEMALE; FLUOROURACIL; HUMANS; KIDNEY NEOPLASMS; LEUCOVORIN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; SAFETY; TREATMENT OUTCOME;

EID: 0037215201     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000066518     Document Type: Article

References (10)

1. Vogelzang NJ, Stadler WM: Kidney cancer. Lancet 1998;352:1691-1696.
2. Negrier S, Escudier B, Lasset C, et al: The FNCLCC Crecy Trial: Interleukin 2 (IL2) + Interferon (IFN) is the optimal treatment to induce responses in metastatic renal cell carcinoma (MRCC). N Engl J Med 1998;338:1272-1278.
3. Chauffert B, Bonnotte B, Chvetzoff G, et al: Réponse majeure d'un cancer du rein métasta-tique à l'association oxaliplatin, 5-fluorouracile et acide L-folinique (FOL-FOX). Presse Méd 1998;27:859.
4. Fizazi K, Ducreux M, Ruffie P, et al: Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer. J Clin Oncol 2000;18:2293-2300.
5. Motzer RJ, Vogelzang NJ: Chemotherapy for renal cell carcinoma; in Raghaven D, Scher HI, Leibel SA, et al (eds): Principles and Practice of Genitourinary Oncology. Philadelphia, Lippincott-Raven, 1997, pp 885-896.
6. Mertens WC, Eisenhauer EA, Moore M, et al: Gemcitabine in advanced renal cell carcinoma: A phase II study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 1993;4:331-332.
7. Einzig AI, Gorowski E, Sasloff J, et al: Phase II trial of taxol in patients with metastatic renal cell carcinoma. Cancer Invest 1991;9:133-136.
8. Chaouche M, Pasturaud AL, Kamioner D, et al: Oxaliplatin, 5-fluorouracil, and folinic acid (folfox) in patients with metastatic renal cell carcinoma. Results of a pilot study. Am J Clin Oncol 2000;23:288-289.
9. Kugler A, Stuhler G, Walden P, et al: Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 2000;6:332-336.
10. Childs R, Chernoff A, Contentin N, et al: Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 2000;343:750-758.